NATERA INC (Common Stock) – ticker 45E - NTRA

Natera Inc. is a diagnostics company specializing in advanced genetic testing services for patients, clinicians, and healthcare systems. The company focuses on analyzing cell-free DNA to support clinical decision-making across several key areas of medicine. Natera’s portfolio includes non-invasive prenatal tests that screen for chromosomal abnormalities, carrier screening tests for inherited genetic conditions, and products supporting in vitro fertilization through pre-implantation genetic testing. It also offers testing for products of conception and non-invasive paternity testing, addressing needs in reproductive health and family planning. Beyond prenatal and fertility applications, Natera provides tests used in oncology and organ health, where circulating DNA analysis can inform monitoring and risk assessment. Headquartered in Austin, Texas, Natera operates primarily through a laboratory services model, working with obstetric, fertility, oncology, and specialty practices, as well as hospital systems and reference laboratories. The company plays a prominent role in the genetic diagnostics market by providing high-complexity tests designed to integrate into routine clinical workflows and support personalized care decisions.